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Available online 21 April 2016Background: The usefulness of bronchoalveolar lavage ﬂuid (BALF) CD4/CD8 ratio for diagnosing sarcoidosis has
been reported in many studies with variable results. Therefore, we performed a meta-analysis to estimate the
overall diagnostic accuracy of BALF CD4/CD8 ratio based on the bulk of published evidence.
Methods: Studies published prior to June 2015 and indexed in PubMed, OVID, Web of Science, Scopus and other
databases were evaluated for inclusion. Data on sensitivity, speciﬁcity, positive likelihood ratio (PLR), negative
likelihood ratio (NLR), and diagnostic odds ratio (DOR) were pooled from included studies. Summary receiver
operating characteristic (SROC) curves were used to summarize overall test performance. Deeks's funnel plot
was used to detect publication bias.
Results: Sixteen publications with 1885 subjects met our inclusion criteria and were included in this meta-
analysis. Summary estimates of the diagnostic performance of the BALF CD4/CD8 ratio were as follows: sensitiv-
ity, 0.70 (95%CI 0.64–0.75); speciﬁcity, 0.83 (95%CI 0.78–0.86); PLR, 4.04 (95%CI 3.13–5.20); NLR, 0.36 (95%CI
0.30–0.44); and DOR, 11.17 (95%CI 7.31–17.07). The area under the SROC curve was 0.84 (95%CI 0.81–0.87).
There was no evidence of publication bias.
Conclusion:Measuring the BALF CD4/CD8 ratiomay assist in the diagnosis of sarcoidosiswhen interpreted in par-
allel with other diagnostic factors.






Sarcoidosis, a chronic inﬂammatory disorder of unknown cause, is
the most frequently observed interstitial lung disease of unknown ori-
gin in Europe (Baughman and Grutters, 2015). It usually affects the
lung and lymphatic system, but its clinical features are varied and
non-speciﬁc, and it shows variable radiographic presentation, all of
whichmakes accurate diagnosis a challenge. Typically, sarcoidosis is di-
agnosed when clinical and/or radiographic ﬁndings are supported by
histological evidence of non-caseating granulomatous inﬂammation,
andwhen other causes of granulomas and local reactions can be reason-
ably excluded (Iannuzzi et al., 2007; Costabel et al., 2008; Am J Respir
Crit Care Med, 1999). Another problem with diagnosing sarcoidosis is
that, unless patients show typical manifestations of Löfgren syndrome,
biopsy is recommended, making diagnosis invasive (Iannuzzi et al.,
2007; Costabel et al., 2008; Am J Respir Crit CareMed, 1999). As a result,ang.scu@gmail.com (F. Wen).
. This is an open access article underinvestigators continue to search for reliable, less invasivemethods to di-
agnose sarcoidosis.
Growing evidence points to the possibility of analyzing the broncho-
alveolar lavage ﬂuid (BALF) to aid in diagnosis. In sarcoidosis, TH1 hy-
perimmune response to an unknown agent causes CD4+ T
lymphocytes to accumulate in affected tissues and leads to the forma-
tion of non-caseating granulomas (Baughman et al., 2003). As a result,
many patients with sarcoidosis show elevated lymphocytosis and
CD4/CD8 ratio in BALF, and this elevated ratio has been associated
with a diagnosis of sarcoidosis (Baughman et al., 2003; Costabel,
1997). Indeed, clinicians may opt not to perform diagnostic biopsy in
patients who present both a clinical picture typical of sarcoidosis and
an elevated BALF CD4/CD8 ratio (Kvale, 2003; Kantrow et al., 1997).
Several studies have suggested that the BALF CD4/CD8 ratio can supple-
ment the results of other tests when diagnosing sarcoidosis (Wells and
Hirani, 2008; Chretien et al., 1985; Stoller et al., 1987).
However, whether the BALF CD4/CD8 ratio can reliably perform as a
diagnostic tool remains controversial. The ratio shows high variability
(Kantrow et al., 1997), and studies of its diagnostic performance suggest
variable sensitivity and speciﬁcity. To gain a clearer picture of thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
303Y. Shen et al. / EBioMedicine 8 (2016) 302–308diagnostic usefulness of this ratio, we performed a meta-analysis to
summarize its overall diagnostic performance based on the available
literature.
2. Methods
This study was performed according to the guidelines of the Pre-
ferred Reporting Items for Systematic Reviews, as well as the Meta-
analysis Statement and methods recommended by the Cochrane Diag-
nostic Test AccuracyWorking Group (Leeﬂang et al., 2008). Institutional
review board approval was not required for this retrospective meta-
analysis.
2.1. Search Strategy
PubMed, OVID, Web of Science, Scopus, Wanfang, Weipu and CNKI
databases were searched for original articles that examined the diag-
nostic performance of BALF CD4/CD8 for sarcoidosis and that were pub-
lished up to October 2015. In PubMed, the search string was
(((Bronchoalveolar lavage OR Bronchoalveolar lavage ﬂuid OR BAL OR
BALF) AND sarcoidosis) AND CD4/CD8 ratio). In OVID, references in
EMBASE from 1974 to June 2015 and in Medline from 1946 to October
2015were searched using the following string: “Bronchoalveolar lavage”
OR “Bronchoalveolar lavage ﬂuid” OR “BAL” OR “BALF” AND “CD4/CD8
ratio” AND “sarcoidosis” AND “sensitivity OR speciﬁcity OR accuracy”.
Search results were limited to human and clinical trials. In Wanfang,
Weipu and CNKI databases, the following search stringwas used: “Bron-
choalveolar lavage ﬂuid” AND “sarcoidosis” AND “CD4/CD8 ratio”. The
“remove duplicates” function was applied during searches in OVID
and the Chinese databases. Additional articles were also searched
using the “related articles” function in PubMed. References within iden-
tiﬁed articles were searched manually to ﬁnd more articles.
2.2. Selection of Publications
We screened titles and abstracts of identiﬁed publications, and those
studies that could not be immediately excluded were retrieved as full
text. Publications were included in our meta-analysis if they fulﬁlled
the following criteria: (1) they used BALF CD4/CD8 ratio for diagnosing
sarcoidosis; (2) they reported sufﬁcient data to calculate true positive
(TP), false positive (FP), false negative (FN), and true negative (TN) of
the BALF CD4/CD8 ratio for diagnosing sarcoidosis; and (3) they consti-
tuted original research published in English or Chinese. To avoid selec-
tion bias, we excluded studies involving fewer than 20 subjects.
Conference abstracts, reviews, editorials, and case reports were also
excluded.
2.3. Data Extraction and Quality Assessment
Two reviewers (YCS and CSP) independently judged the eligibility of
publications and extracted the following data: ﬁrst author, year of pub-
lication, country, number of cases and controls, diagnostic standard,
sample, method, cut-off values, TP, FP, FN, TN, and study design. Dis-
crepancies in data extraction were resolved by consensus. Efforts were
made to contact authors when information was not reported in the ar-
ticle. For studies in which several different cut-off values were tested,
only the data associated with the best diagnostic performance was in-
cluded in this meta-analysis.
The methodological quality of each study was assessed using the
Quality Assessment of Diagnostic Accuracy Studies (QUADAS)-2
(Whiting et al., 2011). This tool consists of four domains: patient selec-
tion, index test, reference standard, as well as ﬂow and timing. Risk of
bias was assessed in four domains, the ﬁrst three of which concern
applicability.2.4. Statistical analysis
Standard methods recommended for diagnostic accuracy meta-
analysis were used (Devillé et al., 2002; Nguyen et al., 2015). We ana-
lyzed the test accuracy of each study by calculating sensitivity, speciﬁc-
ity, positive likelihood ratio (PLR), negative likelihood ratio (NLR),
diagnostic odds ratio (DOR), together with the corresponding 95%CIs.
Summary receiver operating characteristic (SROC) curves and the area
under the curve (AUC) were also calculated (Moses et al., 1993).
Heterogeneity between studies was evaluated using the χ2 test and
Fisher's exact tests. If signiﬁcant heterogeneity existed among studies,
meta-regression analysis was performed using covariates reported in
most included studies: cut-off values, sample size (b100 subjects vs.
≥100 subjects), study design (prospective vs. retrospective), publication
year (before 2005 vs. after 2005), samplingmethod (consecutive vs. not
reported), risk of bias (low vs. high), income in study country (high vs.
low or middle, based on World Bank ranking of national economies),
and ethnicity (Asian vs. Caucasian). Sensitivity analysis was conducted
by subgroups based on the meta-regression results.
Deeks's funnel plot was used to detect publication bias (Deeks et al.,
2005). Post-test probability (PTP)was calculated using the overall prev-
alence of 20% with Fagan nomograms. Three statistical software pro-
grams were used in this meta-analysis: STATA 12.0 (Stata Corp.,
College Station, TX), Meta-DiSc 1.4 (XI, Cochrane Colloquium, Barce-
lona, Spain), and RevMan 5.2 (Cochrane Collaboration, Oxford, UK). All
statistical testswere two-sided, and P b 0.05was considered statistically
signiﬁcant.
2.5. Role of the Funding Source
The funders had no role in the study design, collection, analysis or in-
terpretation of the data, or writing of the report. All authors had access
to the raw data. The corresponding author had full access to all the data
and assumed responsibility for submitting for publication.
3. Results
3.1. Characteristics and Quality of the Included Studies
Fig. 1 outlines the study selection, which led to the inclusion of 16
publications in this meta-analysis (Lee et al., 2015; Suchankova et al.,
2013; von Bartheld et al., 2013; Hyldgaard et al., 2012; De Smet et al.,
2010; Korosec et al., 2010; Danila et al., 2009a; Yao et al., 2008; Heron
et al., 2008; Fireman et al., 2006; Smith et al., 2006a; Greco et al.,
2005; Marruchella and Tondini, 2002; Fireman et al., 1999; He et al.,
1994; Winterbauer et al., 1993). In the studies by Heron et al, BALF
CD4/CD8 ratio was analyzed in an analysis cohort and a validation co-
hort; each was treated as an independent study in our meta-analysis
(Heron et al., 2008). Consequently, 17 studies were meta-analyzed, 12
of which were prospective and 5 retrospective.
Themean sample size of eligible studieswas 111 (range 30–503), in-
volving 999 patients with sarcoidosis and 886 non-sarcoidosis controls.
In all studies, BALF samples were analyzed using ﬂow cytometry. One of
the 17 studies blinded diagnosis of patients (von Bartheld et al., 2013),
while the others did not report blinding. In 10 studies (nine publica-
tions) (Hyldgaard et al., 2012; De Smet et al., 2010; Korosec et al.,
2010; Yao et al., 2008; Heron et al., 2008; Greco et al., 2005;
Marruchella and Tondini, 2002; Fireman et al., 1999; He et al., 1994),
all patients in the case group had biopsy-conﬁrmed sarcoidosis. In
seven studies (Lee et al., 2015; Suchankova et al., 2013; von Bartheld
et al., 2013; Danila et al., 2009a; Fireman et al., 2006; Smith et al.,
2006a; Winterbauer et al., 1993), sarcoidosis was diagnosed based on
the combination of clinical, radiological and pathological evidence: di-
agnosis was based on biopsy showing non-caseating granulomas, after
exclusion of other known causes of granulomatosis. Two studies were
done inmiddle-income countries; the others, in high-income countries.
Fig. 1. Study selection. BALF = Bronchoalveolar lavage ﬂuid.
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mographic information is listed in Supplementary Table 1.
The methodological quality of each study was assessed using
QUADAS-2. When a criterion was fulﬁlled, an answer of Yeswas given,
Unclear if a criterion was unclear or not reported, and No if a criterionTable 1
Summary of studies included in the meta-analysis.
Author/year [ref] Country Ethnicity Cases/controls Method
Lee et al. (2015) South Korea Asian 12/57 FCM
Suchankova et al. (2013) Slovakia Caucasian 26/27 FCM
von Bartheld et al. (2013) Netherlands Caucasian 136/13 FCM
Hyldgaard et al. (2012) Denmark Caucasian 19/83 FCM
De Smet et al. (2010) Belgium Caucasian 36/117 FCM
Korosec et al. (2010) Slovenia Caucasian 47/8 FCM
Danila et al. (2009a) Lithuania Caucasian 318/185 FCM
Yao et al., (2008) China Asian 41/10 FCM
Heron et al., (2008) Netherlands Caucasian 56/63 FCM
Heron et al. (2008) Netherlands Caucasian 26/13 FCM
Fireman et al. (2006) Israel Caucasian 67/53 FCM
Smith et al. (2006a) USA Caucasian 14/12 FCM
Greco et al. (2005) Italy Caucasian 88/76 FCM
Marruchella and Tondini
(2002)
Italy Caucasian 51/38 FCM
Fireman et al. (1999) Israel Caucasian 14/16 FCM
He et al., (1994) China Asian 21/14 FCM
Winterbauer et al. (1993) USA Caucasian 27/101 FCM
BALF = bronchoalveolar lavage ﬂuid; FCM= ﬂow cytometry; FN = false negative; FP = falsewas not achieved. The quality of studies was generally good (Fig. 2),
but three studies were judged to have a high risk of bias in the patient
selection domain (Hyldgaard et al., 2012; Yao et al., 2008; Greco et al.,
2005). Two of these studies also showed high risk of bias related to
ﬂow and timing (Hyldgaard et al., 2012; Yao et al., 2008).Cut-off
value








2.16 11 9 1 48 P Consecutive Low High
3.5 18 1 8 26 P Consecutive Low High
3.5 73 1 63 12 P Consecutive Low High
3.8 13 22 6 61 P Consecutive High High
2.62 24 21 12 96 R Consecutive Low High
3.3 33 1 14 7 P Consecutive Low High
3.5 254 18 64 167 P Consecutive Low High
4 28 3 13 7 R Consecutive High Middle
3 38 17 18 46 P Unknown Low High
3 16 2 10 11 P Unknown Low High
2.5 51 15 16 38 R Unknown Low High
2.3 10 2 4 10 P Unknown Low High
3.5 48 18 40 58 R Consecutive High High
3.5 30 5 21 33 R Consecutive Low High
2.5 14 3 0 13 P Unknown Low High
3.5 18 0 3 14 P Consecutive Low Middle
4 20 17 7 84 P Consecutive Low High
positive; P = prospective; R = retrospective; TN = true negative; TP = true positive.
Fig. 2. Quality assessment of individual studies in terms of risk of bias and applicability
concerns based on the Quality Assessment of Diagnostic Accuracy Studies-2.
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Fig. 3 shows individual study data and provides the Forest plots of
sensitivity and speciﬁcity for using the BALF CD4/CD8 ratio to diagnose
sarcoidosis. Table 2 shows summary estimates of diagnostic performance.Fig. 3. Forest plot of the summary sensitivity and speciﬁcity of BALF CD4/CD8 ratio for the diagno
95%CI is shown as a horizontal line running through the circle. TP = true positive. FP = false pSensitivity ranged from 0.54 to 1.00, and pooled sensitivity was 0.70
(95%CI, 0.64–0.75). Speciﬁcity ranged from 0.70 to 1.00, and pooled
speciﬁcity was 0.83 (95% CI, 0.78–0.86). Pooled PLR and NLR were
4.04 (95%CI, 3.13–5.20) and 0.36 (95%CI, 0.30–0.44), respectively. DOR
was 11.17 (95%CI, 7.31–17.07), and the AUC was 0.84 (95%CI, 0.81–
0.87) (Fig. 4).
3.3. Meta-regression Analysis
Chi-squared values for pooled diagnostic performance parameters
were high: sensitivity, 58.53; speciﬁcity, 31.83; PLR, 33.98; NLR, 50.55;
andDOR, 1.5 × 108 (all P b 0.05). This indicates signiﬁcant heterogeneity
among the included studies (Table 2). In order to identify possible rea-
sons for this heterogeneity, meta-regression was conducted to assess
the effect of study quality on the relative DOR (RDOR) of BALF CD4/
CD8 ratio for diagnosis of sarcoidosis. The characteristics of these covar-
iates are listed in Table 1. Diagnostic accuracy was not signiﬁcantly af-
fected by sample size (P = 0.24), publication year (P = 0.34),
sampling method (P = 0.56), income (P = 0.93), or cut-off value
(P = 0.57). Ethnicity (Asian vs. Caucasian) did not signiﬁcantly affect
RDOR (P = 0.93) Two factors may affect the diagnostic accuracy:
study design (P = 0.048) and risk of bias (P = 0.03). The meta-
regression results are shown in detail in Table 3.
Based on these meta-regression results, we performed sensitivity
analysis by stratifying study participants based on study design and
risk of bias. These two analyses suggested that prospective studies and
high-quality studies (with low risk of bias) reported much better diag-
nostic performance than retrospective studies or studies with high or
uncertain risk of bias (Table 2).
3.4. Publication Bias Evaluation
Deeks's funnel plot asymmetry test was used to assess likelihood of
publication bias in the ﬁnal set of studies. The slope coefﬁcient was as-
sociated with P= 0.75, and the shape of the funnel plot of the pooled
DOR of the CD4/CD8 ratio was not obviously asymmetrical (Fig. 5).
4. Discussion
Numerous studies have focused on the potential value of BALF CD4/
CD8 ratio for diagnosis of sarcoidosis. This is based on the fact that
CD4+T cells interactingwith antigen-presenting cells appear to trigger
formation of sarcoid granulomas and help maintain them (Iannuzzi
et al., 2007; Baughman et al., 2003). In addition, activated alveolarsis of sarcoidosis. The sensitivity/speciﬁcity of each study is represented as a circle, and the
ositive. FN = false negative. TN = true negative. BALF = bronchoalveolar lavage ﬂuid.
Table 2
Summary of overall analysis and sensitivity analysis based on study design and risk of bias.
Total Study design Risk of bias (QUADAS-2)
Prospective Retrospective Low High
Number of studies 17 12 5 14 3
Sensitivity (95%CI) 0.70 (0.64–0.75) 0.72 (0.69–0.76) 0.64 (0.58–0.70) 0.72 (0.69–0.75) 0.60 (0.52–0.68)
Heterogeneitya (P) 58.53 (b0.001) 47.43(b0.001) 8.89 (0.06) 52.46 (b0.001) 2.68 (0.24)
Speciﬁcity (95%CI) 0.83 (0.78–0.86) 0.84 (0.81–0.87) 0.79 (0.74–0.83) 0.84 (0.82–0.87) 0.75 (0.67–0.81)
Heterogeneity (P) 31.83 (0.01) 26.97 (0.005) 4.6 (0.33) 26.66 (0.01) 0.28 (0.87)
PLR (95%CI) 4.04 (3.13–5.20) 4.72 (3.2–6.97) 2.9 (2.28–3.69) 4.48 (3.33–6.04) 2.41 (1.78–3.28)
Heterogeneity (P) 33.98 29.23 (0.002) 3.53 (0.47) 27.17 (0.01) 0.15 (0.93)
NLR (95%CI) 0.36 (0.30–0.44) 0.33 (0.24–0.44) 0.47 (0.38–0.58) 0.35 (0.27–0.44) 0.55 (0.44–0.69)
Heterogeneity (P) 50.55 40.61(b0.001) 5.81 (0.21) 42.55 (b0.001) 1.31 (0.52)
DOR (95%CI) 11.17 (7.31–17.07) 17.43 (9.23–32.56) 6.36 (4.28–9.46) 15.1 (9.12–24.99) 4.45 (2.61–7.60)
Heterogeneity (P) 1.50E + 08 25.16 (0.01) 3.73 (0.44) 27.51 (0.01) 0.49 (0.78)
AUC 0.84 0.87 0.78 0.86 0.77
a Q-value; AUC: Area under the curve; DOR: diagnostic odds ratio; NLR: negative likelihood ratio; PLR: positive likelihood ratio.
306 Y. Shen et al. / EBioMedicine 8 (2016) 302–308macrophages and CD4+ T cells participate in the inﬂux of mononuclear
cells into the alveoli that often precedes sarcoid granuloma formation in
the lung (Baughman et al., 2011; Jones, 2002). Diagnostic studies have
reported highly variable sensitivity and speciﬁcity when using the
CD4/CD8 ratio, prompting us to perform what we believe to be the
ﬁrst meta-analysis to assess the available evidence on the diagnostic
usefulness of this ratio in sarcoidosis.
The pooled results indicate relatively low diagnostic sensitivity of
0.70, and speciﬁcity of 0.83, suggesting a relatively high rate of missed
diagnoses (30%) and misdiagnoses (17%). Likelihood ratios N10 and
b0.1 are considered as strong indicators to rule in or rule out a diagnosis,
respectively (Deeks and Altman, 2004). In the present meta-analysis,
PLR was 4.04 and NLR was 0.36, suggesting relatively low ability to dis-
criminate sarcoidosis from non-sarcoidosis, although the AUC in SROC
analysis was relatively high (0.84). While it appears the BALF CD4/
CD8 ratio is not robust enough on its own to diagnose sarcoidosis,
pooled DOR was moderate (11.17), suggesting that it may be a helpful
ancillary tool that, when interpreted together with other diagnostic fac-
tors, can improve sarcoidosis diagnosis.Fig. 4. Summary receiver operating characteristic (SROC) curve of BALF CD4/CD8 ratio for
the diagnosis of sarcoidosis. Each open circle is the result of a single study. BALF =
bronchoalveolar lavage ﬂuid.QUADAS-2 was used to assess methodological quality of the studies
included in our meta-analysis. QUADAS-2 provides more detailed and
rigorous assessment than the earlier QUADAS, such as in the explana-
tion of indeterminate results. Although this instrument can be used to
assign quality scores (Whiting et al., 2003), it is fundamentally a quali-
tative tool, which we used to characterize risk of bias along four do-
mains as low, high, or unclear. This analysis suggested quality
differences among the included studies, andmeta-regression suggested
that study quality may have affected the reported diagnostic perfor-
mance of the BALF CD4/CD8 ratio. In addition, diagnostic performance
of the BALF CD4/CD8 ratio was variable even among studies at low
risk of bias. These ﬁndings highlight the need for better-designed diag-
nostic studies, particularly prospective studies and studieswith low risk
of bias. These studies should carefully address the issue of variability of
the BALF CD4/CD8 ratio as a diagnostic tool.
The studies included in this meta-analysis varied in their cut-off
values for the CD4/CD8 ratio, which usually fell between 2 and 4. No in-
ternational standards exist about what cut-off value to use, and this
value is likely to vary with clinical context, depending on country, eth-
nicity, examination equipment, disease severity, and history of cortico-
steroid treatment. Our meta-regression of cut-off values suggests that
different cut-off values did not substantially affect the diagnostic accu-
racy of the BALF CD4/CD8 ratio (P = 0.57, Table 2). This contrastsTable 3
Meta-regression of the diagnostic accuracy of BALF CD4/CD8 ratio.
Covariate No. of studies Coefﬁcient RDOR (95%CI) P
Sample size
≥100 8 −0.61 0.54 (0.19–1.58) 0.24
b100 9
Study design
Prospective 12 −0.91 0.40 (0.16–0.99) 0.048
Retrospective 5
Publication year
After 2005 13 −0.59 0.55 (0.15–2.02) 0.34
Before 2005 4
Sampling method
Consecutive 12 0.34 1.41 (0.42–4.75) 0.56
Unknown 5
Risk of Bias
Low 14 1.14 3.12 (1.12–8.7) 0.03
High 3
Income
High 15 0.08 1.08 (0.15–7.68) 0.93
Low/middle 2
Cut-off value
3–4 13 −0.35 0.70 (0.19–2.59) 0.57
b3 or N4 4
Ethnicity 0.08 1.08 (0.15–7.68) 0.93
Asian 2
Caucasian 15
BALF: bronchoalveolar lavage ﬂuid. RDOR: relative diagnostic odds ratio
Fig. 5. Funnel plots for assessing the risk of publication bias. The funnel graph shows the
log of the diagnostic odds ratio (DOR) plotted against the standard error of the log of
the DOR (an indicator of sample size). Solid circles represent each study in the meta-
analysis. The line indicates the regression result.
307Y. Shen et al. / EBioMedicine 8 (2016) 302–308with previous studies showing that a CD4/CD8 ratio ≥ 3.5 strongly sug-
gests sarcoidosis, but is not speciﬁc enough on its own to diagnose the
disease (Marruchella and Tondini, 2002; Costabel et al., 2010). Further
work should aim to identify the cut-off value that provides optimal di-
agnostic accuracy, and researchers should be open to the possibility
that different cut-offs are needed for different types of patients or clini-
cal contexts. In addition, all included studies utilized ﬂow cytometry to
determine the BALF CD4/CD8 ratio based on a protocol developed for
peripheral blood samples. Several studies have reported that ﬂow cyto-
metric typing of lymphocytes from BALF correlates well with results
from conventional immunocytochemistry (Brandt et al., 1996; Ma
et al., 2001; Smith et al., 2006b; Szpechcinski et al., 2011), though the re-
sults may depend on combinations of antibodies and gating strategies.
Therefore future studies are needed to optimize these parameters for
typing lymphocytes in BALF.
There are several factors that should be addressed which may inﬂu-
ence the BALF CD4/CD8 ratio. One factor is smoking, which is associated
with higher total cell number, higher proportions of CD8+ lymphocytes
and CD4+ cells, and lower CD4+/CD8+ ratio in BALF (Hoser et al.,
1999). Numbers of CD4+ and CD8+ cells in BALF are also affected in
smokerswith comorbidities such as chronic obstructive pulmonary dis-
ease (Forsslund et al., 2014). Several studies included in this meta-
analysis reported smoking history, while its effect on BALF CD4/CD8
ratio remains unclear (Korosec et al., 2010; Fireman et al., 2006). Future
studies should examine the potential impact of smoking on BALF cell
numbers and proportions, and thereby on the potential diagnostic use-
fulness of the BALF CD4/CD8 ratio. Another factor was the stage of sar-
coidosis. As pulmonary sarcoidosis advances from stage I to stage III,
the number of CD8+ cells increases and the number of CD4+ cells de-
creases, leading to a decrease in the CD4/CD8 ratio (Danila et al., 2008).
Indeed, previous work has shown that the diagnostic sensitivity of the
BALF CD4/CD8 ratio decreases with increasing stage of sarcoidosis
(Danila et al., 2009a); on the other hand, the ratio may be less clinically
useful in stage I disease, for which clinical and radiographic features on
their own show high diagnostic reliability. A third factor that should be
addressed is the recovery rate of BALF,whichhas been reported to range
widely from 23.3% to 91.3% (Fireman et al., 2006; Winterbauer et al.,
1993). Most studies included in ourmeta-analysis did not report the re-
covery rate, which may bias diagnostic accuracy. A fourth factor was
whether or not participants were on corticosteroid treatment, which
can modify lymphocyte proportions in BALF and thereby the BALF
CD4/CD8 ratio (Danila et al., 2009b). Indeed, some studies suggest thatthis ratio shows lower diagnostic sensitivity in patients on such
treatment (Danila et al., 2009a; He et al., 1994). None of the patients
in nine studies (eight publications) received corticosteroids
(Suchankova et al., 2013; De Smet et al., 2010; Korosec et al., 2010;
Yao et al., 2008; Heron et al., 2008; Fireman et al., 2006; Fireman
et al., 1999; Winterbauer et al., 1993), while the other studies did not
report corticosteroid status (Lee et al., 2015; von Bartheld et al., 2013;
Hyldgaard et al., 2012; Smith et al., 2006a; Greco et al., 2005;
Marruchella and Tondini, 2002). Future studies should take into account
possible confounding by smoking status, recovery rate, and corticosteroid
treatment when assessing the diagnostic performance of BALF CD4/CD8
ratio. Studies should also look systematically at whether the ratio is
more clinically useful for advanced stages of the disease, where clinical
and radiographic features on their own can be less informative.
The ﬁndings of this meta-analysis should be interpreted with cau-
tion because of several limitations. First, we excluded conference ab-
stracts, reviews, editorials, case reports and articles not written in
English or Chinese, which may bias our results. In addition, we omitted
unpublished studies and studies not indexed in our set of databases.
Nevertheless, our funnel plots suggested no signiﬁcant risk of publica-
tion bias. Second, there may have been misclassiﬁcation bias. The diag-
nosis of sarcoidosis in the case group was biopsy-conﬁrmed in only 12
studies (11 publications); in the remaining ﬁve studies (Lee et al.,
2015; Suchankova et al., 2013; Danila et al., 2009a; Fireman et al.,
2006; Smith et al., 2006a), sarcoidosis was diagnosed based on the com-
bination of clinical, radiological, pathological and follow-up observation.
Some cases lacked histological evidence of non-caseating granulomas.
Third, most studies in our meta-analysis did not report blinding,
which increases the risk of analytical bias. Future diagnostic studies
should avoid these methodological problems. Future studies should
also examine the cost-effectiveness of determiningBALF lymphocyte ra-
tios relative to more invasive biopsy, as well as compare the ratio with
endobronchial ultrasound transbronchial needle aspiration, which has
been shown to be a safe and effective diagnostic procedure (Costabel
et al., 2010; Agarwal et al., 2012).
In conclusion, our meta-analysis provides the most comprehensive
evidence to date that the determination of the BALF CD4/CD8 ratio can
aid in the diagnosis of sarcoidosis, with an elevated ratio associated
with greater likelihood of disease in patients who present a typical clin-
ical/radiological picture of the disease. However, the ratio is not speciﬁc
or selective enough to use on its own; rather, it must always be com-
bined with other established diagnostic factors and tests.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2016.04.024.Author Contributions
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